One-year follow-up study of Helicobacter pylori eradication rate with 13C-urea breath test after 3-d and 7-d rabeprazole-based triple therapy

World Journal of Gastroenterology

Volumn 11, Issue 11, 2005, Pages 1680-1684

  Wang, Hwang Huei ^a   Chou, Jen Wei ^a   Liao, Kuan Fu ^a   Lin, Zong Yi ^a   Lai, Hsueh Chou ^a   Hsu, Chang Hu ^a   Chen, Chih Bin ^a  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Eradication rate; Short term triple therapy

Indexed keywords

AMOXICILLIN; BACTERIAL DNA; CARBON 13; CLARITHROMYCIN; RABEPRAZOLE; UREASE;

ADULT; ARTICLE; BITTER TASTE; CHILL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC KIT; DIARRHEA; DRUG DOSE REGIMEN; ENDOSCOPY; ERADICATION THERAPY; FEMALE; FOLLOW UP; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOUTH DISEASE; PEPTIC ULCER; RANDOMIZED CONTROLLED TRIAL; TASTE DISORDER; ULCER HEALING; UREA BREATH TEST;

EID: 17144400839     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i11.1680     Document Type: Article

References (43)

1. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 1: 1311-1315
2. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA 1994; 272: 65-69
3. Blaser MJ. Helicobacter pylori and the pathogenesis of gastroduodenal inflammation. J Infect Dis 1990; 161: 626-633
4. Gisbert JP, Pajares JM, Losa C. Helicobacter pylori and gastroesophageal reflux disease: Friends or foes? Hepatogastroenterology 1999; 46: 1023-1029
5. Bouzourene H, Haefliger T, Delacretaz F, Saraga E. The role of Helicobacter pylori in primary gastric MALT lymphoma. Histopathology 1999; 34: 118-123
6. An international association between Helicobacter pylori infection and gastric cancer. The EUROGAST Study Group. Lancet 1993; 341: 1359-1362
7. Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: A review. Gastroenterology 1996; 110: 1244-1252
8. Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998; 13: 1-12
9. Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, Lai KC, Hu WH, Yuen ST, Leung SY, Fong DY, Ho J, Ching CK, Chen JS. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: A randomized controlled trial. JAMA 2004; 291: 187-194
10. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group. Gut 1997; 41: 8-13
11. Lind T, Veldhuyzen van Zanten S, Unge P, Spiller R, Bayerdorffer E, O'Morain C, Bardhan KD, Bradette M, Chiba N, Wrangstadh M, Cederberg C, Idstrom JP. Eradication of Helicobacter pylori using one-wk triple therapies combining omeprazole with two antimicrobials: The MACH I Study. Helicobacter 1996; 1: 138-144
12. Miwa H, Ohkura R, Murai T, Nagahara A, Yamada T, Ogihara T, Watanabe S, Sato N. Effectiveness of omeprazole-amoxicillin-clarithromycin (OAC) therapy for Helicobacter pylori infection in a Japanese population. Helicobacter 1998; 3: 132-138
13. Hsieh YH, Lin HJ, Tseng GY, Perng CL, Chang FY, Lee SD. A 3-d anti-Helicobacter pylori is a good alternative for bleeding peptic ulcer patients with Helicobacter pylori infection. Hepatogastroenterology 2001; 48: 1078-1081
14. Grimley CE, Penny A, O'Sullivan M, Shebani M, Lismore JR, Cross R, Illing RC, Loft DE, Nwokolo CU. Comparison of two 3-d Helicobacter pylori eradication regimens with a standard 1-wk regimen. Aliment Pharmacol Ther 1999; 13: 869-873
15. Miwa H, Ohkura R, Murai T, Sato K, Nagahara A, Hirai S, Watanable S, Sato N. Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole. Aliment Pharmacol Ther 1999; 13: 741-746
16. Kositchaiwat C, Ovartlarnporn B, Kachintorn U, Atisook K. Low and high doses of rabeprazole vs omeprazole for cure of Helicobacter pylori infection. Aliment Pharmacol Ther 2003; 18: 1017-1021
17. Vakil N, Lanza F, Schwartz H, Barth J. Seven-d therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther 2004; 20: 99-107
18. Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL. Acid inhibition on the first d of dosing: Comparison of four proton pump inhibitors. Aliment Pharmacol Ther 2003; 17: 1507-1514
19. Welage LS. Pharmacologic properties of proton pump inhibitors. Pharmacotherapy 2003; 23 (10 Pt 2): 74S-80S
20. Lara LF, Cisneros G, Gurney M, Van Ness M, Jarjoura D, Moauro B, Polen A, Rutecki G, Whittier F. One-d quadruple therapy compared with 7-d triple therapy for Helicobacter pylori infection. Arch Intern Med 2003; 163: 2079-2084
21. Wermeille J, Cunningham M, Armenian B, Zelger G, Buri P, Merki H, Hadengue A. Failure of 1-d high-dose quadruple therapy for cure of Helicobacter pylori infection. Aliment Pharmacol Ther 1999; 13: 173-177
22. Prakash A, Faulds D. Rabeprazole. Drugs 1998; 55: 261-267
23. Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ. Comparison of rabeprazole 20 mg vs omeprazole 20 mg in the treatment of active gastric ulcer-a European multicentre study. The European Rabeprazole study group. Aliment Pharmacol Ther 1998; 12: 789-795
24. Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ. Comparison of rabeprazole 20 mg vs omeprazole 20 mg in the treatment of active duodenal ulcer: A European multicentre study. The European Rabeprazole study group. Aliment Pharmacol Ther 1999; 13: 179-186
25. Tsutsui N, Taneike I, Ohara T, Goshi S, Kojio S, Iwakura N, Matsumaru H, Wakisaka-Saito N, Zhang HM, Yamamoto T. A novel action of the proton pump inhibitor rabeprazole and its thioether derivative against the motility of Helicobacter pylori. Antimicrob Agents Chemother 2000; 44: 3069-3073
26. Gambaro C, Bilardi C, Dulbecco P, Iiritano E, Zentilin P, Mansia C, Usai P, Vigneri S, Savarino V. Comparable Helicobacter pylori eradication rates obtained with 4- and 7-d rabeprazole-based triple therapy: A preliminary study. Dig Liver Dis 2003; 35: 763-767
27. Yang KC, Wang GM, Chen JH, Chen TJ, Lee SH. Comparison of rabeprazole-based four- and seven-d triple therapy and omeprazole-based seven-d triple therapy for Helicobacter pylori infection in patients with peptic ulcer. J Formos Med Assoc 2003; 102: 857-862
28. Isomoto H, Furusu H, Morikawa T, Mizuta Y, Nishiyama T, Omagari K, Murase K, Inoue K, Murata I, Kohno S. 5-d vs 7-d triple therapy with rabeprazole, clarithromycin and amoxicillin for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 14: 1619-1623
29. Wong BC, Wong WM, Yee YK, Hung WK, Yip AW, Szeto ML, Li KF, Lau P, Fung FM, Tong TS, Lai KC, Hu WH, Yuen MF, Hui CK, Lam SK. Rabeprazole-based 3-d and 7-d triple therapy vs omeprazole-based 7-d triple therapy for the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2001; 15: 1959-1965
30. Rauws EA, van der Hulst RW. Current guidelines for the eradication of Helicobacter pylori in peptic ulcer disease. Drugs 1995; 50: 984-990
31. Working Party of the European Helicobacter pylori study group. Guidelines for clinical trials in Helicobacter pylori infection. Gut 1997; 41(Suppl 2): S1-9
32. Moayyedi P, Chalmers DM, Axon AT. Patient factors that predict failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori. J Gastroenterol 1997; 32: 24-27
33. Queiroz DM, Dani R, Silva LD, Santos A, Moreira LS, Rocha GA, Correa PR, Reis LF, Nogueira AM, Alvares Cabral MM, Esteves AM, Tanure J. Factors associated with treatment failure of Helicobacter pylori infection in a developing country. J Clin Gastroenterol 2002; 35: 315-320
34. Alarcon T, Domingo D, Lopez-Brea M. Antibiotic resistance problems with Helicobacter pylori. Int J Antimicrob Agents 1999; 12: 19-26
35. Mendonca S, Ecclissato C, Sartori MS, Godoy AP, Guerzoni RA, Degger M, Pedrazzoli J Jr. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline, and furazolidone in Brazil. Helicobacter 2000; 5 79-83
36. Malfertheiner P, Peitz U, Treiber G. What constitutes failure for Helicobacter pylori eradication therapy? Can J Gastroenterol 2003; 17(Suppl B): 53B-57B
37. Mollison LC, Stingemore N, Wake RA, Cullen DJ, McGechie DB. Antibiotic resistance in Helicobacter pylori. Med J Aust 2000; 173: 521-523
38. Megraud F. Resistance of Helicobacter pylori to antibiotics: The main limitation of current proton-pump inhibitor triple therapy. Eur J Gastroenterol Hepatol 1999; 11(Suppl 2): S35-S37
39. Teo EK, Fock KM, Ng TM, Khor CJ, Tan AL. Metronidazole-resistant Helicobacter pylori in an urban Asian population. J Gastroenterol Hepatol 2000; 15: 494-497
40. Ellenrieder V, Boeck W, Richter C, Marre R, Adler G, Glasbrenner B. Prevalence of resistance to clarithromycin and its clinical impact on the efficacy of Helicobacter pylori eradication. Scand J Gastroenterol 1999; 34: 750-756
41. Osato MS, Reddy R, Graham DY. Metronidazole and clarithromycin resistance amongst Helicobacter pylori isolates from a large metropolitan hospital in the United States. Int J Antimicrob Agents 1999; 12: 341-347
42. Bode G, Hoffmeister A, Koenig W, Brenner H, Rothenbacher D. Characteristics of differences in Helicobacter pylori serology and 13C-urea breath-testing in an asymptomatic sample of blood donors. Scand J Clin Lab Invest 2001; 61: 603-608
43. Chey WD, Murthy U, Toskes P, Carpenter S, Laine L. The 13C-urea blood test accurately detects active Helicobacter pylori infection: A United Sates multicenter trial. Am J Gastroenterol 1999; 94: 1522-1524